maria luz calibo
Sep 22, 2011

Mylan enters settlement and license deal with Roche over Xeloda - Pharmaceutical and Biotechnology News - Pharma Letter

US generic drugs giant Mylan (Nasdaq: MYL) says that it has entered into a settlement and license agreement with Swiss pharma major Roche (ROG: SIX), resolving litigation related to Xeloda (capecitabine) tablets, 150mg and 500mg, USP, an orally administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers.